Clesrovimab
id:
clesrovimab-201-6825946
title:
Clesrovimab
text:
Clesrovimab (MK-1654) is a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infections. Developed by Merck, it is in a phase III trial as of 2023. It works differently than nirsevimab.
brand slug:
wiki
category slug:
encyclopedia
description:
Monoclonal antibody
original url:
https://en.wikipedia.org/wiki/Clesrovimab
date created:
date modified:
2024-04-24T19:56:40Z
main entity:
{"identifier":"Q123530159","url":"https://www.wikidata.org/entity/Q123530159"}
image:
fields total:
13
integrity:
14